Multicenter Retrospective Analysis of Systemic Chemotherapy for Advanced Poorly Differentiated Neuroendocrine Carcinoma of Digestive System

#620

Introduction: No standard chemotherapy is established for advanced poorly differentiated neuroendocrine carcinoma (PDNEC) originating from the gastrointestinal tract (GI) or the hepato-biliary-pancreatic system (HBP).

Aim(s): This retrospective study investigated outcomes of GI/HBP-PDNEC patients treated with systemic chemotherapy.

Materials and methods: Selection criteria were: 1) histologically proven PDNEC, small cell carcinoma, mixed endocrine-exocrine carcinoma with a PDNEC component, or histologically proven neuroendocrine tumor with rapid progression; 2) primary tumor arising from GI or HBP; 3) unresectable or recurrent disease treated with systemic chemotherapy between April 2000 and March 2011.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Tomohiro Y

Authors: Yamaguchi T, Machida N, Kasuga A, Takahashi H, Sudo K,

Keywords: poorly-differentiated, PDNEC, irinotecan, etoposide, gastrointestinal,